European Archives - Page 861 of 1108 - European Medical Journal

Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Through Phase 2 Trials

Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Through Phase 2 Trials

SOTIO Broadens Its Phase II Clinical Trial Program in Ovarian Cancer

Prague, Czech Republic, 28 November, 2017 – SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the first patient…

Orchard Therapeutics Announces Extension of its Collaboration with Manchester University to Include Sanfilippo Syndrome Type B

London & Manchester, UK, 27 November, 2017 – Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company…

EMJ

Tackling the Inflammatory Burden of Psoriasis: A Multidisciplinary Approach

The symposium took place on 15th September 2017 as part of the European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.

How to Implement Guidelines into Clinical Practice

National and international guidelines are available for almost all common diseases, and these should be applied when counselling patients.

The Treatment Approach of Idiopathic Inflammatory Myopathies

This commentary reflects our personal approach to the treatment of idiopathic inflammatory myopathies (IIM), also commonly referred to as myositis.

Sustaining Cancer Care Through Collaborative Stewardship

Cancer care has undergone rapid changes in recent years, providing dramatically improved outcomes for many patients.

Tackling the Inflammatory Burden of Psoriasis: A Multidisciplinary Approach

Prof Girolomoni provided an overview of psoriasis, considering how patients are frequently affected by other comorbidities.

Hereditary Angioedema: The Dawn of a New Era of Hereditary Angioedema Management

This symposium provided an overview of past, current, and future therapies and routes of administration for patients with hereditary angioedema (HAE).

Developments in the Treatment and Management of Psoriasis

The oral session consisted of a talk on the 2-year efficacy and safety of guselkumab in the treatment of moderate-to-severe psoriasis from the Phase III VOYAGE 1 trial.